Sign In
Buy ALDX
$1.86
+0.220 (+13.41%)
At Close: Jun 03, 2026
BOX Gears Up to Report Q3 Earnings: What's in the Offing?
01:32pm, Friday, 01'st Dec 2023
BOX's fiscal third-quarter results are likely to reflect strength in content cloud solutions.
Invest In Penny Stocks? Is It Worth It & 4 To Watch Now
02:12pm, Tuesday, 07'th Nov 2023
If you're looking for penny stocks to invest in right now, you've got your work cut out for you. That's because the initial strategy when approaching cheap stocks is to trade them in the short term in
5 Most Active Penny Stocks Today & Why They're Moving Now
02:11pm, Wednesday, 01'st Nov 2023
Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures.
Why Are Stocks Up Today?
10:47am, Wednesday, 01'st Nov 2023
Stocks are up today as investors prepare for the latest information from the Federal Reserve concerning interest rates. The Federal Open Market Committee (FOMC) meeting taking place today will result
Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?
10:34am, Wednesday, 01'st Nov 2023
Aldeyra Therapeutics (NASDAQ: ALDX ) stock is on the rise Wednesday after entering into an exclusive option agreement with AbbVie (NYSE: ABBV ). This agreement covers the option for AbbVie to acquire
Aldeyra Therapeutics stock plunges on heavy volume after FDA finds ‘substantive' issues with NDA for dry-eye disease treatment
11:50am, Monday, 16'th Oct 2023
Shares of Aldeyra Therapeutics Inc. ALDX, -66.43% plummeted 61.9% toward a 3 1/2-year low in very active morning trading Monday, enough to pace the Nasdaq's decliners, after the Massachusetts-based bi
Aldeyra Therapeutics stock tanks on warning that FDA will reject new drug application
11:27am, Monday, 16'th Oct 2023
Shares of Aldeyra Therapeutics (NASDAQ:ALDX) have lost two-thirds of their value Monday after the company warned the US Food and Drug Administration may not approve its new drug application. Minutes
Aldeyra:Upcoming PDUFA, Strong NDA, Long Pipeline, Decent Cash
07:44pm, Friday, 22'nd Sep 2023
Aldeyra is a late-stage company developing therapies for immune-mediated diseases, with a focus on dry eye disease and allergic conjunctivitis. Their lead asset, reproxalap, is under NDA review for dr
Aldeyra Therapeutics: Navigating The Future Of Eye Disease Treatment With Reproxalap
12:49am, Monday, 10'th Jul 2023
Aldeyra Therapeutics reported $165 million in cash and cash equivalents as of March 31, 2023, with a net loss of $15.6 million for Q1 2023. The company's drug, reproxalap, is under FDA review for trea
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, June 29, 2023, at 8:00 a.m. (ET) to provi
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, June 27, 2023, at 8:00 a.m. (ET) to provid
Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study
11:35am, Friday, 16'th Jun 2023
Aldeyra (ALDX) soars on meeting primary and secondary endpoints in the late-stage study of reproxalap for patients with allergic conjunctivitis.
Aldeyra's Stellar Allergic Conjunctivitis Results To Raise Reproxalap Monetization Value
10:55am, Friday, 16'th Jun 2023
Aldeyra Therapeutics reported positive results from a Phase III study of Reproxalap, an eye drop drug for allergic conjunctivitis and dry eye disease that provides immediate relief to patients. The tr
Biotech Stock Surges on Eye Treatment Study
11:31am, Thursday, 15'th Jun 2023
Aldeyra Therapeutics Inc (NASDAQ:ALDX) is up 14.1% at $11.93 at last glance, after the biotech's allergy treatment in the form of liquid eye drops, reproxalap, met its goal in a late-stage study.
Aldeyra Therapeutics stock surges as reproxalap for allergic conjunctivitis trial meets primary endpoint
10:49am, Thursday, 15'th Jun 2023
Aldeyra Therapeutics (NASDAQ:ALDX) announced on Thursday that its investigational new drug reproxalap ophthalmic solution for patients with allergic conjunctivitis has achieved statistical significanc
